Navigation Links
Drug dilemma confronts users of painkillers

The Food and Drug Administration announced that Vioxx - Merck's blockbuster painkiller, would include new information on its label. The FDA said that Merck can claim that Vioxx has fewer gastrointestinal complications// than one older non-steroidal anti-inflammatory drug, naproxen. But the FDA also decided that the Vioxx label must mention that it might be linked to an increased risk of heart attack or high blood pressure.

Manufacturer Merck & Company got good news, too: Vioxx can advertise that it's gentler to the stomach than an older competitor and that it relieves the pain of rheumatoid arthritis in addition to the more common osteoarthritis. Vioxx and another popular competitor, Celebrex, work differently than older, cheaper painkillers known to cause stomach ulcers.

Merck had fought for over a year to be allowed to say Vioxx is gentler to the stomach. Finally, the FDA agreed that an 8,000-patient study found Vioxx users had half the risk of ulcers as users of the older naproxen. The same study found Vioxx users had twice the risk of heart attacks or other cardiovascular side effects than naproxen patients.

Merck argued that Vioxx isn't bad, but that naproxen offered the added benefit of thinning the blood a little, which Vioxx doesn't do. Studies also show Vioxx can increase the risk of high blood pressure, and that people who use higher-than-recommended doses are more at risk for certain side effects.
'"/>




Page: 1

Related medicine news :

1. A ray of hope in Angioplasty dilemma
2. Safeguarding anti-inflammatory users from ulcers
3. Personality profiles of gamblers and substance abusers are similar
4. Women complain Viagra users want too much sex
5. Morphine Withdrawal Complicates Hepatitis C Infection in Drug Abusers
6. Children Of Alcoholics Tend to Become Drug Abusers In Adulthood
7. UN Warns of HIV epidemic among Asia-Pacific drug users
8. Lack of treatment for cocaine users
9. Reinfection with Hepatitis C Stopped in drug users
10. Calcitriol [Vitamin D] with combination of painkillers for cancer treatment
11. Codeine-based painkillers to be used cautiously
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drug dilemma confronts users painkillers

(Date:10/30/2014)... , A mathematical model developed by NIH grantees predicts ... to prevent HIV infection via vaginal sex, whereas just ... infection via anal sex. This finding helps explain why ... PrEP, in women failed to show efficacy. Participants in ... of Truvada and tenofovir (another antiretroviral) for HIV prevention ...
(Date:10/30/2014)... October 30, 2014 Graphics, coding, typography ... synonymous with the craft of web design and require ... Yet a simpler solution to create a website can ... videos, contact information, customer reviews and Facebook posts all ... "It is the next evolution of how a business ...
(Date:10/30/2014)... 30, 2014 Five months after their ... Street LLC announces new branding and a website to ... . After David Mepham’s promotion to name partner earlier ... website to include Mepham’s name and better reflect their ... mediation firm, the decision to implement new branding reflects ...
(Date:10/30/2014)... Radio listeners who indicate use of four ... of traditional radio commercials and have overwhelmingly endorsed custom ... a purchasing decision. , Those are some highlights from ... radio marketing company CRN International. The research is now ... respondents who indicated they have purchased or considered purchase ...
(Date:10/30/2014)... Thompson HealthDay Reporter WEDNESDAY, ... Liberia -- one of three West African nations ravaged by ... said Wednesday. Dr. Bruce Aylward, WHO,s assistant director general, ... in Liberia and no increase in laboratory-confirmed cases. He said ... the epidemic may be making some progress, The New ...
Breaking Medicine News(10 mins):Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... , , WICHITA, Kan., ... public that late-term abortionist LeRoy Carhart will not be granted a transfer ... hours after Operation Rescue launched a pet i ... that Wesley Medical Center deny late-term abortionist LeRoy Carhart hospital or transfer ...
... RIVER EDGE, N.J., Aug. 14 Nephros, Inc. (OTC Bulletin Board: NEPH) announced today ... Recent Highlights , , , ... , Issued four new patents , ... , "2009 has continued to be a productive year for Nephros," said ...
... , , , , ... US: ADL), a U.S.-based pharmaceutical company with major operations in China, ... Rule 12b-25 of the Securities Exchange Act of 1934, as amended, ... Report on Form 10-Q for the second quarter ended June 30, ...
... , Visit by Lung Cancer ... , WASHINGTON, Aug. 14 /PRNewswire-USNewswire/ -- Today, Lung ... has signed on as a cosponsor of a bill to establish the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO ) , , ...
... effective with few side effects, study finds , FRIDAY, ... called Levadex is an effective treatment for migraines, according ... trial, conducted at the Jefferson Headache Center at Thomas ... who took the drug had greater relief from symptoms ...
... , WASHINGTON, Aug. 14 The Sixth ... of an Ohio law strictly regulating the provision of the dangerous ... CEO and President of Americans United for Life, stated, "This is ... providers have readily admitted that they administer RU-486 in violation of ...
Cached Medicine News:Health News:Operation Rescue: Wesley Medical Center Promises To Keep Carhart, Abortions Out 2Health News:Nephros Reports 2009 Second Quarter Financial Results 2Health News:Nephros Reports 2009 Second Quarter Financial Results 3Health News:Nephros Reports 2009 Second Quarter Financial Results 4Health News:Nephros Reports 2009 Second Quarter Financial Results 5Health News:AMDL Inc. Files Notification of Late Filing for Form 10-Q 2Health News:Senator Ben Nelson (D-NE) Joins as Co-Sponsor of Lung Cancer Mortality Reduction Act 2Health News:Senator Ben Nelson (D-NE) Joins as Co-Sponsor of Lung Cancer Mortality Reduction Act 3Health News:Americans United for Life Applauds Decision Protecting Women From Dangers of RU-486 2
(Date:10/30/2014)... VIEW, Calif. , Oct. 30, 2014 /PRNewswire/ ... accelerated dramatically as a result of government initiatives ... time - healthcare providers have invested over the ... the heart of health IT, and U.S. clinicians ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... the third quarter ended September 30, 2014 on Thursday, ... markets. Howard Robin , president and chief executive ... results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. ... and a live audio-only Webcast of the conference call ...
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
Breaking Medicine Technology:Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
... Ltd. (Amex:,SVA), a leading provider of biopharmaceutical products ... trials for its pandemic influenza,vaccines. Sinovac received approval ... Drug Administration (SFDA) to commence Phase Ib and ... inactivated vaccine and Phase I and,II trials of ...
... of Proprietary siRNA Molecule in Acute ... ... Inc., a,development-stage pharmaceutical company focused on discovering and,developing novel RNA interference-based ... its proprietary product,candidate, AKIi-5, a siRNA compound discovered and developed by ...
Cached Medicine Technology:Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4
...
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
It is lightweight and portable headlight option for office exam room. It offers complete comfort and portability....
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
Medicine Products: